Matthew Herper

President-elect Trump suggested in an interview that he shares some of the concerns voiced by RFK Jr. about the safety of some childhood vaccines

Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head randomized controlled trial.

If there is a message in President-elect Trump’s Friday night reveal of who he intends to nominate for key health care positions in his administration, it

Under RFK Jr., insiders say CDC is the most vulnerable target, while FDA changes would be slower.

Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.

Merck's new formulation could help secure a larger share of Keytruda's sales after the cancer drug's U.S. patent expires in 2028.

.@nes047 and @NathanielEDavid formed Jupiter Bioventures to quickly test out, and if necessary discard, ideas in biotech.

Facing with a dialogue with RFK Jr., a top FDA official mounts a public defense of vaccines — and pleads for open minds.

23andMe, the genetics startup that has repeatedly captured the public imagination and then faced nearly fatal business challenges, announced it would lay off 40% of its workforce.

What will a second Donald Trump presidency mean for the regulation of medicines in the U.S.? History isn’t likely to repeat itself, but it will rhyme.

CVS Health is running out of time to answer an existential question about its strategy.

A doctor inspired by his own fight against a rare malignancy to scour thousands of existing drugs to see if they can cure other diseases has a powerful new ally: Janet Woodcock, who for decades was one of the most influential figures at the Food and Drug Administration

What Pfizer’s decision to pull its sickle cell drug means for patients, the company, and the FDA.

More than once 23andMe's Anne Wojcicki has saved the company from corporate disaster. Can she do it again?

Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.

After being criticized for profligate post-pandemic spending, the company is "pacing" itself to focus on launches of key medicines.

Two former Verily executives say that they are starting a new initiative, Highlander Health, to push forward an effort decades in the making.

Summit’s lung cancer treatment has wowed researchers. The CEO behind it is a living challenge to the assumptions of many in biotech.

Kathy Giusti was diagnosed with multiple myeloma in 1996 and told she had three years to live. Twenty-eight years later, Giusti, 65, is thriving.

With new vaccine data released Tuesday, Vaxcyte, a San Carlos, Calif.-based firm, emerged as one of biotechnology’s hottest David-vs.-Goliath stories as